Tillkännagivande • Dec 04
MEDINET Co., Ltd. announced that it expects to receive ¥12.39 million in funding from Macquarie Bank Limited MEDINET Co., Ltd announced a private placement to issue 590,000 units of 20th Stock Acquisition rights at a price of ¥21 per stock acquisition right for aggregate gross proceeds of ¥12,390,000 on December 3, 2025. The transaction has been approved by the board of directors and is expected to close on December 23, 2025. The exercise period for the stock acquisition rights will be between December 24, 2025 to December 23, 2027. The transaction will include participation from Macquarie Bank Limited. Tillkännagivande • Nov 13
MEDINET Co., Ltd., Annual General Meeting, Dec 17, 2025 MEDINET Co., Ltd., Annual General Meeting, Dec 17, 2025. Tillkännagivande • Nov 05
MEDINET Co., Ltd. to Report Fiscal Year 2025 Results on Nov 13, 2025 MEDINET Co., Ltd. announced that they will report fiscal year 2025 results on Nov 13, 2025 Tillkännagivande • Jul 08
MEDINET Co., Ltd. to Report Q3, 2025 Results on Aug 12, 2025 MEDINET Co., Ltd. announced that they will report Q3, 2025 results on Aug 12, 2025 New Risk • Jun 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2018 fiscal period end). Share price has been highly volatile over the past 3 months (9.4% average weekly change). Minor Risk Market cap is less than US$100m (JP¥10.3b market cap, or US$71.2m). Tillkännagivande • Apr 15
MEDINET Co., Ltd. to Report Q2, 2025 Results on May 13, 2025 MEDINET Co., Ltd. announced that they will report Q2, 2025 results on May 13, 2025 Tillkännagivande • Jan 18
MEDINET Co., Ltd. to Report Q1, 2025 Results on Feb 13, 2025 MEDINET Co., Ltd. announced that they will report Q1, 2025 results on Feb 13, 2025 Tillkännagivande • Nov 13
MEDINET Co., Ltd., Annual General Meeting, Dec 18, 2024 MEDINET Co., Ltd., Annual General Meeting, Dec 18, 2024. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2018 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (5.4% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥12.1b market cap, or US$81.0m). Tillkännagivande • Jun 22
MEDINET Co., Ltd. to Report Q3, 2024 Results on Aug 09, 2024 MEDINET Co., Ltd. announced that they will report Q3, 2024 results on Aug 09, 2024 Tillkännagivande • Jan 11
MEDINET Co., Ltd. to Report Q1, 2024 Results on Feb 09, 2024 MEDINET Co., Ltd. announced that they will report Q1, 2024 results on Feb 09, 2024 Tillkännagivande • Nov 13
MEDINET Co., Ltd., Annual General Meeting, Dec 21, 2023 MEDINET Co., Ltd., Annual General Meeting, Dec 21, 2023. New Risk • Nov 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2018 fiscal period end). Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (JP¥11.4b market cap, or US$75.5m). New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2018 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (JP¥11.3b market cap, or US$77.6m). New Risk • Jul 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥14.3b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2018 fiscal period end). Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Market cap is less than US$100m (JP¥14.3b market cap, or US$99.4m). New Risk • Jun 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2018 fiscal period end). Minor Risk Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Tillkännagivande • Jun 17
MEDINET Co., Ltd. to Report Q3, 2023 Results on Jul 31, 2023 MEDINET Co., Ltd. announced that they will report Q3, 2023 results on Jul 31, 2023 Tillkännagivande • Feb 09
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2023 MEDINET Co., Ltd. provided earnings guidance for the year ending September 30, 2023. For the year ending September 30, 2023, the company expects net sales of JPY 728 million, operating loss of JPY 1,766 million and loss of JPY 1,761 million or JPY 8.32 per basic share. Tillkännagivande • Dec 26
MEDINET Co., Ltd. to Report Q1, 2023 Results on Feb 09, 2023 MEDINET Co., Ltd. announced that they will report Q1, 2023 results on Feb 09, 2023 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Outside Director Kouichiro Yoshino was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 12
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2023 MEDINET Co., Ltd. provided earnings guidance for the year ending September 30, 2023. For the year, the company expects net sales of JPY 728 million, Operating loss of JPY 1,766 million, loss of JPY 1,761 million and basic loss per share of JPY 8.32. Tillkännagivande • Nov 11
MEDINET Co., Ltd., Annual General Meeting, Dec 15, 2022 MEDINET Co., Ltd., Annual General Meeting, Dec 15, 2022. Tillkännagivande • Sep 24
MEDINET Co., Ltd. to Report Q4, 2022 Results on Nov 11, 2022 MEDINET Co., Ltd. announced that they will report Q4, 2022 results on Nov 11, 2022 Tillkännagivande • Jun 16
MEDINET Co., Ltd. to Report Q3, 2022 Results on Aug 10, 2022 MEDINET Co., Ltd. announced that they will report Q3, 2022 results on Aug 10, 2022 Tillkännagivande • May 13
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2022 MEDINET Co., Ltd. provided earnings guidance for the year ending September 30, 2022. For the year, the company expects net sales of JPY 752 million, Operating loss of JPY 1,755 million, loss of JPY 1,761 million and basic loss per share of JPY 9.85. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Outside Director Kouichiro Yoshino was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Apr 08
MEDINET Co., Ltd. to Report Q2, 2022 Results on May 12, 2022 MEDINET Co., Ltd. announced that they will report Q2, 2022 results on May 12, 2022 Tillkännagivande • Feb 11
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2022 MEDINET Co., Ltd. provided earnings guidance for the year ending September 30, 2022. For the period, the company expects net sales of JPY 752 million, operating loss of JPY 1,755 million, loss of JPY 1,761 million and basic loss per share of JPY 9.85. Tillkännagivande • Sep 02
MEDINET Co., Ltd. announced that it has received ¥22.44 million in funding from Macquarie Bank Limited, Investment Arm On September 1, 2021, MEDINET Co., Ltd. closed the transaction. Tillkännagivande • Aug 17
MEDINET Co., Ltd. announced that it expects to receive ¥22.44 million in funding from Macquarie Bank Limited, Investment Arm MEDINET Co., Ltd. announced a private placement of 340,000 18th stock acquisition rights at ¥66 per stock acquisition right for gross proceeds of ¥22,440,000 on August 16, 2021. The transaction included participation from returning investor Macquarie Bank Limited, Investment Arm. The potential shares from the issuance of stock acquisition rights will be 34,000,000 shares. The initial exercise price of stock acquisition rights ¥78.85 for a period from September 2, 2021 to September 1, 2023. The transaction will happen through third party allocation. The company will incur issuance expenses with respect to the transaction including registration and license taxes, attorney's fees, fair value calculation costs for the stock acquisition rights, securities registration statement preparation costs, etc. The issue date for stock acquisition rights will be September 1, 2021. The transaction has been approved at board of directors’ meeting of the company. Is New 90 Day High Low • Feb 18
New 90-day high: JP¥72.00 The company is up 6.0% from its price of JP¥68.00 on 20 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is up 4.0% over the same period. Is New 90 Day High Low • Dec 07
New 90-day low: JP¥61.00 The company is down 39% from its price of JP¥100.00 on 08 September 2020. The Japanese market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 8.0% over the same period. Tillkännagivande • Nov 14
MEDINET Co., Ltd., Annual General Meeting, Dec 17, 2020 MEDINET Co., Ltd., Annual General Meeting, Dec 17, 2020. Tillkännagivande • Sep 23
MEDINET Co., Ltd. to Report Fiscal Year 2020 Results on Nov 06, 2020 MEDINET Co., Ltd. announced that they will report fiscal year 2020 results on Nov 06, 2020 Tillkännagivande • Sep 08
MEDINET Co., Ltd. announced that it has received ¥24.13 million in funding from Macquarie Bank Limited, Investment Arm On September 7, 2020, MEDINET Co., Ltd. (TSE:2370) closed the transaction. Tillkännagivande • Aug 22
MEDINET Co., Ltd. announced that it expects to receive ¥24.13 million in funding from Macquarie Bank Limited, Investment Arm MEDINET Co., Ltd. (TSE:2370) announced a private placement of 190,000 units 17th stock acquisition rights at a price of ¥127 per share for the gross proceeds of ¥24,130,000 with returning investor Macquarie Bank Limited, Investment Arm on August 21, 2020. The 17th stock acquisition rights will be converted into 19,000,000 shares at a price of ¥100 per stock acquisition right. The minimum exercise price of stock acquisition rights is ¥54 and the initial exercise price ¥101.12. The exercise period is from September 8, 2020 to September 7, 2022. The transaction has been approved by board of directors of the company. The transaction is expected to close on September 7, 2020. Tillkännagivande • Jul 08
MEDINET Co., Ltd. announced that it has received ¥24.436 million in funding from Macquarie Bank Limited, Investment Arm On July 6, 2020, MEDINET Co., Ltd. (TSE:2370) closed the transaction. Tillkännagivande • Jun 29
MEDINET Co., Ltd. to Report Q3, 2020 Results on Aug 07, 2020 MEDINET Co., Ltd. announced that they will report Q3, 2020 results on Aug 07, 2020 Tillkännagivande • Jun 20
MEDINET Co., Ltd. announced that it expects to receive ¥24.436 million in funding from Macquarie Bank Limited, Investment Arm MEDINET Co., Ltd. (TSE:2370) announced a private placement of 164,000 units 16th stock acquisition rights at a price of ¥149 per share for the gross proceeds of ¥24,436,000 on June 19, 2020. The transaction will include participation from returning investor Macquarie Bank Limited, Investment Arm. The transaction has been approved by board of directors. The 16th stock acquisition rights will be converted into 16,400,000 shares at a price of ¥100 per stock acquisition right. The minimum exercise price of stock acquisition rights is ¥62 and the initial exercise price ¥113.78. The exercise period is from July 7, 2020, to July 6, 2022. The company will pay issuance expenses ¥15,000,000 in the transaction. The transaction is expected to close on July 6, 2020. 